RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced an update on the progress regarding the non-binding term sheet the Company received and previous announced on June 26, 2020 to divest the remaining shares it holds in its Polish subsidiary, Helix Immuno-Oncology S.A.
20200930 – HBP Press Release – Polish Subsidiary Divestitutre Update